Investigational New Drug Application
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent. Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the company's Investigational New... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:
Source: benzinga.com